Background-Alterations in Ca 2ϩ -handling proteins are thought to underlie the deranged Ca 2ϩ transients that contribute to deterioration of cardiac function in congestive heart failure (CHF). Clinical trials in CHF patients have shown that treatment with ␤-adrenergic receptor antagonists (␤B) improves cardiac performance. The present study determined whether the abundance of Ca 2ϩ -handling proteins is different in failing hearts from patients treated or untreated with ␤B. Methods and Results-Ca 2ϩ regulatory protein abundance was compared in LV myocardium of 10 nonfailing hearts (NF group) and 44 failing hearts (CHF group) removed at transplantation. Analysis was performed in ␤B-treated (␤B-CHF) and non-␤B treated (non-␤B-CHF) patients and in 4 subgroups: ischemic cardiomyopathy (ICM, nϭ10), nonischemic dilated cardiomyopathy (DCM, nϭ10), ICM with ␤B therapy (␤B-ICM, nϭ12), and DCM with ␤B therapy (␤B-DCM, nϭ12). Sarcoplasmic reticulum Ca 2ϩ ATPase, phospholamban, and Na ϩ -Ca 2ϩ exchanger protein abundance were determined by use of Western blot analysis. Ca 2ϩ transients were measured with fluo-3. Sarcoplasmic reticulum Ca 2ϩ ATPase was significantly less abundant whereas phospholamban and Na ϩ -Ca 2ϩ exchanger were not significantly altered in non-␤B-CHF versus NF. Sarcoplasmic reticulum Ca 2ϩ ATPase in the ␤B-ICM and ␤B-DCM was greater than in non-␤B-CHF and were not different than in NF. Ca 2ϩ transients in non-␤B-CHF myocytes had significantly smaller peaks and were prolonged versus NF myocytes. Ca 2ϩ transients from ␤B-CHF myocytes had shorter durations than in ␤B-CHF myocytes.
P rogressive deterioration of cardiac pump function is a central feature of congestive heart failure (CHF). Depression of myocyte contractility is thought to underlie much of the poor pump performance of the failing human heart. 1, 2 A recent study has shown that treatment of CHF patients with ␤-adrenergic receptor antagonists (␤-blockers [␤B]) improves cardiac function and ventricular geometry and thereby slows (or in some cases may reverse) progression of CHF. 3 Cellular and molecular bases for these ␤B effects are not well understood. Our working hypothesis is that ␤B slow (or reverse) progression of myocyte contractile defects in failing human heart.
Abnormal Ca 2ϩ homeostasis appears to be primarily responsible for depression of myocyte contractility in CHF. 4 -6 Peak systolic Ca 2ϩ is smaller, rate of decay of the Ca 2ϩ transient is slower, and diastolic Ca 2ϩ can be elevated in failing versus normal ventricular myocytes, especially at faster heart rates. 6 These observations support the hypothesis that alterations in abundance or activity of molecules that regulate systolic and diastolic Ca 2ϩ are centrally involved in depressed contractility of failing heart.
Although the idea that abnormal Ca 2ϩ regulation contributes to depressed cardiac performance in human CHF is well established, cellular and molecular bases of aberrant Ca 2ϩ homeostasis have not been identified clearly. 2 The mostfrequently studied Ca 2ϩ -regulatory molecules have been sarcoplasmic reticulum (SR) Ca 2ϩ ATPase (SERCA), SERCA regulatory protein phospholamban (PLB), sarcolemmal Na ϩ / Ca 2ϩ exchanger (NCX), sarcolemmal L-type Ca 2ϩ channels, and SR Ca 2ϩ release channel (ryanodine receptor). Changes in the abundance or function of these molecules in human heart failure have been variable in previous studies. [7] [8] [9] [10] [11] [12] [13] [14] In this regard, SERCA mRNA and protein abundance have been reported to be smaller in failing versus nonfailing human ventricular muscle in some studies, 8 -11 whereas others have found no significant differences. [12] [13] [14] The present research examined the hypothesis that chronic ␤B therapy in CHF patients improves myocyte Ca 2ϩ regulation and contractility by normalizing expression of myocyte Ca 2ϩ regulatory proteins. The aim of the present research was to measure and to compare the protein abundance of SERCA, PLB, and NCX in nonfailing and failing human ventricular muscle (obtained at time of cardiac transplantation) from patients that either were or were not being treated with ␤B.
Methods

Patients and Tissue Preparation
Protein was isolated from transmural LV myocardium from 10 nonfailing (NF group) unused donor hearts and 44 failing hearts. A total of 20 CHF patients were not (non-␤B-CHF) and 24 were receiving ␤B therapy (␤B-CHF). Ten patients had ischemic dilated cardiomyopathy (ICM) and were not receiving ␤B therapy (ICM group); 12 had ICM and were receiving ␤B therapy (␤B-ICM group). Ten had nonischemic dilated cardiomyopathies (DCM) and were not receiving ␤B therapy (DCM group); 12 had DCM and were receiving ␤B therapy (␤B-DCM group).
Protein Assay
Tissue was homogenized in PBS lysis buffer containing 2% SDS (Fisher Biotech), 1% Igepal CA-630 (Sigma Chemical Co), 0.5% deoxycholate (Sigma), 5 mmol/L EDTA, and proteinase inhibitors (10 g/mL aprotinin, 10 g/mL leupeptin, 1 mmol/L phenylmethylsulfonyl fluoride, 5 g/mL pepstatin A, 8 g/mL calpain inhibitor I and II, and 200 g/mL benzamidine). Supernatant was assayed for total protein, 15 mixed with SDS sample buffer (2% SDS, 0.1 mol/L tris-Cl (pH 6.8), 20% glycerol, 100 mmol/L DTT, and 0.02% bromphenol blue) and stored at Ϫ70°C. Studies that used isolated human myocytes 16, 17 and nonmyocytes used identical techniques.
Western Blot Analysis
Total protein was separated by SDS-PAGE in a buffer that contained 25 mmol/L tris base, 190 mmol/L glycine, and 0.1% SDS and transferred to nitrocellulose in a buffer that contained 25 mmol/L tris base, 190 mmol/L glycine, and 20% methanol. Nonspecific binding was blocked with TBST buffer (0.1% Tween 20, 137 mmol/L NaCl, 2.7 mmol/L KCl, and 25 mmol/L tris base, pH 7.6) that contained 5% nonfat milk. Targeted antigens were probed with monoclonal antibodies; SERCA (gift from Dr Kevin P. Campbell, University of Iowa, Iowa City), PLB (Upstate Biotechnology), NCX (Swant), cardiac ␣-sarcomeric actin (Sigma Immuno Chemicals), and GAPDH (Biogenesis). Antibodies were labeled with horseradish peroxidase by anti-mouse Ig secondary antibody, 1:2000 dilution (Amersham Life Science). Targeted antigens were visualized with enhanced chemiluminescence assay (NEN Life Science). Cellular specificity of all antibodies was tested in LV tissue, isolated myocytes, and isolated ventricular nonmyocytes. SERCA, PLB, NCX, and cardiac actin could not be detected in nonmyocytes (data not shown). GAPDH was observed in every sample.
Films were scanned (Epson Expression 636), and band intensities were quantified with densitometric analysis by use of the NIH Image 1.62f program. Targeted bands were normalized to cardiac actin and GAPDH.
Intracellular Ca 2؉ Measurements
Fluo-3 was used to measure changes in cytosolic free Ca 2ϩ (37°C) induced by 500-ms voltage-clamp steps through patch pipettes as described previously. 16 -18 
Statistical Analysis
Analysis of NF versus CHF samples was with an unpaired 2-tailed Student t test. Follow-up subgroup analyses (3 group, 5 group) was by ANOVA with pairwise analysis. A Bonferroni multiple comparison was used to locate significant differences among groups. A value of PϽ0.05 was set for statistical significance.
Results
Patient Characteristics
CHF duration was greatest in ␤B-DCM patients (see Table  1 ). Heart weight/body weight ratio (HW/BW) was significantly greater in CHF (nϭ44) than NF (nϭ10; 6.7Ϯ 0.25 versus 4.9Ϯ 0.4; PϽ0.01). When patients were sorted by disease and treatment, HW/BW was greater in non-␤Btreated CHF patients than in those with NF hearts. HW/BW of ␤B-treated CHF hearts were also greater than in NF hearts and less than in non-␤B-treated CHF hearts. However, these differences were not significant. Ejection fraction (EF) was significantly smaller in all CHF groups versus NF patients.
Average ␤B dosages and other medications are listed in Table 2 . Of the CHF patients, Ͼ90% required intravenous inotropic agents at time of transplantation, and 5 of 10 NF patients were receiving dopamine for blood pressure support.
SERCA, PLB, and NCX in NF Versus CHF LV Samples
Ca 2ϩ regulatory protein abundance was first compared in NF (nϭ10) versus all CHF (nϭ44) samples (Figure 1 ). Substantial patient-to-patient variability occurred in abundance of SERCA, PLB, and NCX within the CHF group. Despite this variability, SERCA (SERCA/actin) was significantly less abundant in CHF versus NF muscles (Figure 2A ), whereas PLB ( Figure 2B ) and NCX ( Figure 2C) were not significantly different.
PLB interacts with SERCA and inhibits its Ca 2ϩ transport rate. 19 Phosphorylation of PLB relieves this inhibition. The relative abundance of these 2 proteins and level of PLB phosphorylation influences Ca 2ϩ homeostasis and cardiac myocyte contractility. 20 -22 Therefore, SERCA/ PLB ratio should reflect Ca 2ϩ transport capacity of the SR. SERCA/PLB was significantly smaller in CHF versus NF samples ( Figure 2D ).
SERCA and NCX compete for cytoplasmic Ca 2ϩ during the Ca 2ϩ transient 23 and a high SERCA/NCX activity is associated with rapid decay of the Ca 2ϩ transient. Decreases in SERCA/NCX activity should reduce the size and slow the decay rate of the Ca 2ϩ transient. SERCA/NCX protein abundance of CHF samples was smaller but not significantly different from NF samples ( Figure 2E ).
CHF samples were grouped with respect to absence or presence of ␤B treatment and compared with NF samples. Representative data are shown in Figures 3A and 3B and averages in Figure 4 . SERCA was significantly less abundant in non-␤B-CHF than in NF but there was no difference between NF and ␤B-CHF groups (Figure 4A ). PLB and NCX were more abundant in non-␤B-CHF than in ␤B-CHF or NF samples but these differences were not statistically significant ( Figures 4B and 4C ). SERCA/PLB and SERCA/NCX were significantly smaller in non-␤B-CHF than in NF or ␤B-CHF samples, and no significant differences were seen between NF and ␤B-CHF samples ( Figures 4D and 4E) .
CHF samples finally were subgrouped with respect to origin of disease and absence or presence of ␤B treatment ( Figures 3A and 3B ). SERCA abundance in ICM and DCM patients who did not receive ␤B was significantly less than in NF muscles ( Figure 5A ). Among DCM patients who received ␤B drugs SERCA abundance was significantly greater than in non-␤B disease-matched counterparts. SERCA abundance in ␤B-treated patients was less than but not significantly different than in NF hearts ( Figure 5A ). Similar results were obtained when SERCA (and all other proteins) were normalized by GAPDH (data not shown).
PLB (sum of pentameric and monomeric forms) and NCX protein abundance were greater in non-␤B-treated ICM and DCM than in either NF or ␤B-treated muscles ( Figures 5B  and 5C ), but these differences failed to reach statistical significance. Identical results were obtained when PLB pentameric and monomeric forms were analyzed individually.
Ratios of SERCA/PLB and SERCA/NCX protein abundance were significantly smaller in ICM and DCM CHF patients versus NF hearts ( Figures 5D and 5E ). SERCA/PLB and SERCA/NCX protein abundance in ␤B-treated patients was significantly greater than in disease-matched non-␤B patients and was not significantly different than in NF hearts ( Figures 5D and 5E ). Actin/total protein abundance was also significantly smaller in ICM versus NF (see Figure 3 ).
Ca 2؉ Transients in NF, Non-␤B-CHF, and ␤B-Treated-CHF Myocytes
Peak systolic Ca 2ϩ was smaller, Ca 2ϩ transient duration was longer, and rate of decay of the transient was slower in non-␤B-CHF versus NF myocytes ( Figure 6 ). Ca 2ϩ transients in ␤B-CHF myocytes had a shorter duration and faster rate of decay than non-␤B-CHF myocytes, and these were not different from NF. Peak systolic Ca 2ϩ was only modestly (PϾ0.05) greater in ␤B-CHF versus non-␤B-CHF myocytes. These experiments were performed with control of the magnitude and duration of depolarization because differences in AP duration have a significant effect on the decay of the Ca 2ϩ transient in failing human ventricular myocytes through the NCX. 17 Therefore, the faster rate of Ca 2ϩ transient decay in ␤Bversus non-␤B-CHF myocytes probably reflects enhanced SR Ca 2ϩ transport.
Discussion
The present data support the hypothesis that ␤B treatment of CHF patients can improve myocyte Ca 2ϩ handling by normalizing the abundance of Ca 2ϩ -regulatory proteins. Major observations are (1) that SERCA protein was significantly less abundant in CHF patients not receiving ␤B than in NF patients, (2) that SERCA protein abundance was significantly greater in CHF patients treated with ␤B than in CHF patients not receiving ␤B, (3) that SERCA/PLB and SERCA/NCX were significantly smaller in non-␤B CHF versus NF and greater in ␤B-CHF versus non-␤B-CHF patients, (4) that Ca 2ϩ transients were smaller and decayed more slowly in non-␤B CHF versus NF myocytes, and (5) that Ca 2ϩ transients in ␤B-CHF myocytes had significantly faster rates of decay than non-␤B CHF myocytes. These results strongly support the idea that deranged Ca 2ϩ homeostasis in human CHF involves alterations in abundance and activity of SR Ca 2ϩ transport proteins and suggests that some of these changes can be reversed with ␤B therapy. Our observations also suggest a potential mechanism (improved myocyte Ca 2ϩ regulation) for the consistent yet unexplained finding that ␤B improve LV function in failing human hearts. 24
Ca 2؉ -Handling Protein Abundance and Ca 2؉ Transients in CHF
Previous studies [7] [8] [9] [10] [11] [12] [13] [14] have shown marked variability in the abundance of SERCA, PLB, and NCX proteins among patients with CHF. Our findings of more uniform results when ␤B treatment is taken into account suggest that some of this variability is related to treatment effects superimposed on disease-related alterations.
Reduction in SERCA/PLB and SERCA/NCX in CHF myocytes can explain the reduced peak and slower decay of the Ca 2ϩ transient we observed in failing myocytes. Partial normalization of Ca 2ϩ regulatory protein abundance in ␤B-CHF myocytes can also explain the improved rate of decay of their Ca 2ϩ transients. These findings support the hypothesis that the reduced abundance of SERCA protein disrupts the balance of Ca 2ϩ transport between SERCA and NCX to produce defective Ca 2ϩ homeostasis, 2,7,20 -22 with an increased reliance on NCX 16, 17, 25 in failing human ventricular myocytes.
How Do ␤B Work in CHF Patients?
Heightened sympathetic nerve activity in CHF helps maintain cardiac output and mean blood pressure in the face of intrinsic defects in cardiac function. 26 -27 However, sustained sympathetic activity in CHF is thought to produce abnormalities in adrenergic signaling and cell physiology 3 (including abnormal Ca 2ϩ handling). The bases of these adrenergic cascaderelated myocyte abnormalities are largely unknown. Similarly, although chronic ␤B agents are effective in the treatment of heart failure, 3 cellular mechanisms for their beneficial effects on cardiac function likewise are unexplained. For example, chronic treatment with carvedilol is particularly effective for improvement of LV EF among CHF patients, but this agent does not produce the alterations in ␤-adrenergic receptor density observed with other ␤B, 28 which implies modifications in myocyte phenotype at a level beyond the adrenergic receptor.
Our present study design was inadequate to prove that ␤B cause beneficial changes in cardiocyte Ca 2ϩ regulatory gene expression. However, our findings support a link between normalization of Ca 2ϩ homeostasis and ␤B treatment in CHF patients. 29 We cannot rule out the possibility that the pattern of Ca 2ϩ regulatory gene expression in NYHA class IV CHF patients is highly variable and that only those patients with high SERCA/PLB and SERCA/NCX tolerate ␤B therapies. Arguing against such a selection bias is the fact that ␤Bassociated increases in SERCA/PLB ratio did not correlate with EF measured before transplantation. In addition, a recent study by Gwathmey et al, 30 in which 1 month of treatment with the ␤B carteolol increased SERCA activity and cardiac function in myopathic turkey hearts, supports a causal link between ␤B therapy and expression of Ca 2ϩ regulatory proteins.
We can only speculate about a mechanism for normalization of SERCA protein abundance produced by ␤B treatment. This mechanism could involve elimination of ␤-adrenergic receptor-mediated repression of myocyte SERCA expression. ␤B also could reduce apoptosis, 31 thereby increasing the number of functional myocytes. Still another possibility is that ␤B could be working through nonmyocytes to eliminate expression of factors that depress myocyte function by decreasing SERCA expression.
Why Are ␤B-Treated Hearts Still Failing?
Our results suggest that improved heart function in ␤B clinical trials 3, 24, 29 involves normalization of aberrant Ca 2ϩ regulatory protein abundance. We speculate that in early CHF, the beneficial effects of ␤B on Ca 2ϩ -handling proteins mediate increased EF and promote beneficial remodeling. However, our data also suggest that CHF still can progress to the point at which transplantation is required in ␤B-treated patients with normalized (or partially normalized) myocyte Ca 2ϩ handling.
Potential explanations as to why patients with ␤B treatment still required transplantation are as diverse as the mechanisms contributing to the syndrome of advanced CHF. Loss of myocytes through necrosis or apoptosis may overwhelm improvements in Ca 2ϩ handling. Similarly, ongoing defects in cardiac perfusion or life-threatening arrhythmias may necessitate transplantation despite improvements in contractile function of remnant myocytes. Within the myocyte, abnormalities of electrophysiology, ultrastructure, metabolism, signaling, phosphorylation, or myofilament properties may persist despite improvements in abundance of dysregulated Ca 2ϩ -handling proteins. Within and beyond the heart, detrimental neurohormone and cytokine activation, vasoconstriction, and other peripheral abnormalities may drive progression of the syndrome.
Limitations
We could not control the types or concentrations of the medications that the patients were receiving. In this regard, 22 of 24 ␤B-CHF patients were receiving either metoprolol 16 or carvedilol. 6 Interestingly, normalization of Ca 2ϩ regulatory protein abundance was similar in all ␤B-treated patients, which suggests a common mechanism. Importantly, we were unable to find a correlation between SERCA protein abundance and any other medication, including drugs that interfere with angiotensin signaling. Finally, intravenous inotropic agents, particularly milrinone (in 12 of 24 patients) did not preclude the normalized pattern of SERCA abundance in ␤B-treated patients.
Summary and Conclusions
CHF patients (NYHA class IV) not treated with ␤B had less SERCA protein than did those with NF hearts, and their Ca 2ϩ transients were abnormal. In CHF patients treated with ␤␤, SERCA abundance was not different than in the NF hearts, and their Ca 2ϩ transients were improved. These findings suggest that ␤B-CHF therapy may cause improved cardiac performance by normalizing expression of Ca 2ϩ regulatory proteins. Our observations also suggest that conventional pharmacotherapy may produce the "molecular remodeling" currently being sought through gene therapy. 32, 33 Potential for long-term improvements in Ca 2ϩ homeostasis in patients with NYHA class IV symptoms of heart failure also supports the use of novel adjuvants, including phosphodiesterase inhibitors 34 or mechanical circulatory support 35 to help establish ␤B therapy in these clinically tenuous patients.
